AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$PAHC

Phibro Animal (PAHC) Q1 2027 Earnings Call Transcript

Phibro Animal Health (PAHC) reported Q1 2027 sales growth of 6% to $386.8M and adjusted EBITDA growth of 4% to $64.3M. Performance Products and Mineral Nutrition segments drove growth, while Animal Health saw a 3% increase. The company maintained its full-year guidance and expects protein demand to grow, despite near-term pressure on producer profitability.

Original reporting
finance.yahoo.com
Published Nov 7, 2026, 5:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 5:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Phibro Animal (PAHC) Q1 2027 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PAHCNeutralMed
01

Why it matters

Earnings beat on net income and stable guidance suggest limited immediate price movement, but inventory reduction and Brazil regulatory updates could influence future quarters.

02

Market read

Primary earnings disclosure for a mid‑cap animal health company; provides fresh financial data and guidance for traders.

03

What to watch

Potential upside from pending Virginiamycin approval in Brazil and inventory reduction plans could drive future earnings.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Phibro Animal Health Corp (PAHC) presented its Q1 2027 earnings call, highlighting segment performance and full‑year outlook.

Company-level read

Ticker impact

$PAHCNeutralHigh confidence
Context

Q1 2027 earnings release with sales of $386.8M, adjusted EBITDA $64.3M and FY guidance unchanged.

Expected impact

likely modest neutral to slight positive pressure as market prices in solid earnings and unchanged guidance

Evidence & confidence

Numbers beat expectations on net income; guidance unchanged reduces surprise, so price move expected to be limited.

Market effects

Sector

Animal health sector may see modest uplift as PAHC reports solid growth in mineral nutrition and performance products.

Regional

U.S. animal health market may experience slight positive sentiment; Brazil regulatory update noted but limited impact.

Global

Limited to specialty nutrition and animal health investors; no broad market effect.

Counterpoint

What could challenge this read

Despite earnings beat, unchanged guidance may signal limited upside; a short position could be justified if market expectations were higher.

Key entities

  • Executive
    Dani Bendheim

    President and CEO who presented the earnings.

  • Executive
    Glenn David

    Provided detailed financial commentary during the call.

Read at source← All news

Also covered by

1 outlet

Related articles

$PAHCHighAI 8/10

Phibro Animal Health Corp (PAHC) (Q1 2027) Earnings Call Highlights: Solid Start to Fiscal

Phibro Animal Health (PAHC) reported Q1 2027 sales of $386.8M (+6%) and adjusted EBITDA of $64.3M (+4%). CEO Donnie Bantine expects Brazil Virginiamycin approval but no sales assumed in 2027. Zoetis portfolio drove MFA growth, while livestock margins are squeezed. USDA's border reopening impacts cattle imports. Net income rose 11% to $29.5M. Guidance remains unchanged, with net sales expected between $1.55B-$1.6B.

finance.yahoo.com
$PAHCMed

What Phibro Animal Health (PAHC) Said on Its Q1 Earnings Call

Phibro Animal Health (PAHC) reported Q1 adjusted EBITDA fell $1M due to higher SG&A expenses, despite increased gross profit. Mineral Nutrition and Performance Products sales rose 17% and 16%, respectively, with EBITDA gains. Companywide operating income declined $1.6M. Phibro maintained fiscal 2027 guidance, with net sales expected between $1.55B and $1.6B. Brazilian regulatory discussions continue, with no sales included in the forecast. Free cash flow was $22M over the past year.

finance.yahoo.com
$PAHCHighAI 8/10

Phibro Animal Health (NASDAQ:PAHC) exceeds Q3 CY2026 expectations

Phibro Animal Health (PAHC) reported Q3 CY2026 revenue of $386.8M, beating estimates by 3% and growing 6.3% year-on-year. Adjusted EPS met expectations at $0.79. Adjusted EBITDA rose 3.9% to $64.3M. The company reconfirmed its full-year revenue guidance of $1.58B and adjusted EPS guidance of $3.50, with EBITDA guidance of $263M, above analyst estimates.

finance.yahoo.com
$PAHCMed

Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance

PHIBRO ANIMAL HEALTH CORP (PAHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ For Immediate Release ​ Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance ​ TEANECK, N.J., November 4, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced

SEC EDGAR 8-K
$PAHCMedAI 8/10

Phibro Animal Health (PAHC) Sets 2027 Guidance, Is The Stock Still A Bargain?

Phibro Animal Health (PAHC) issued 2027 guidance, projecting net sales of $1.55b-$1.60b and net income of $122m-$132m. The company reported 2026 sales of $1.518b and net income of $99.72m. Analysts' price targets range from $38 to $58, with a consensus of $45.60, suggesting a 16.1% undervaluation. The stock has seen a 90-day return of 17.95% and a 3-year return above 200%.

yahoo.com